Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab

医学 贝伐单抗 外显子组 肿瘤科 阿替唑单抗 肝细胞癌 索拉非尼 内科学 帕博西利布 靶向治疗 外显子组测序 癌症 彭布罗利珠单抗 免疫疗法 化疗 乳腺癌 基因 转移性乳腺癌 生物 突变 生物化学
作者
Wendy Limousin,Pierre Laurent‐Puig,Marianne Ziol,Nathalie Ganne‐Carrié,Pierre Nahon,Amal Ait-Omar,Olivier Séror,Sabrina Sidali,Claudia Campani,Pierre Blanc,Alban Lermine,Laëtitia Marisa,Jessica Zucman‐Rossi,Jean‐Charles Nault
出处
期刊:Journal of Hepatology [Elsevier BV]
卷期号:79 (6): 1450-1458 被引量:62
标识
DOI:10.1016/j.jhep.2023.08.017
摘要

•Whole-genome/exome and RNA sequencing of tumor biopsies is feasible for patients with HCC and H-CCK in clinical practice. •A small subset of patients with HCC and H-CCK received a targeted therapy adapted to genomic alterations. •We identified a clinical benefit of targeted treatment in 3/19 patients with analyzable genomic data. Background & Aims The “French Medicine Genomic program 2025” has been designed to give patients with cancers that are refractory to systemic treatments access to off-label therapies adapted to their specific genomic profile. Herein, we reported the results of this program in patients with advanced hepatocellular carcinoma (HCC) and hepato-cholangiocarcinoma (H-CCK). Methods In one center, all patients with HCC or H-CCK who progressed under atezolizumab/bevacizumab with available tumor frozen samples benefited from whole-genome/-exome and RNA sequencing. Targeted therapies were matched to genomic alterations following the recommendations of a molecular tumor board and radiological response and overall survival were assessed. Results Among 135 patients with HCC and H-CCK treated by atezolizumab/bevacizumab, 20 patients benefited from genomic analysis after progression (16 HCC; 4 H-CCK). Nineteen patients had analyzable data, 70% were male, median age was 57 years, 65% had metastatic disease and 45% had vascular invasion. Among these 19 patients, 14 patients (76%) harbored at least one actionable genomic alteration and 9/14 received an adapted targeted therapy (45%). One patient with H-CCK showing CDK4 amplification was treated with palbociclib and achieved a partial radiological response for 16 months. Another patient with H-CCK, high HER2 overexpression and a high homologous recombination score was treated with trastuzumab/olaparib and had stable disease. One patient with an HCC and bi-allelic inactivation of TSC2 achieved a complete radiological response under everolimus. The remaining six treated patients (all HCC) had progressive disease, including three patients treated with trametinib, two with everolimus and one with olaparib. Conclusion Molecular-based guided therapy is feasible in patients with HCC/H-CCK progressing under atezolizumab/bevacizumab and may be useful in a small subset of patients. Impact and implications The use of whole-genome/-exome and RNA sequencing in clinical practice has not been reported in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma. Herein, we performed a pilot study which suggested that whole-genome/-exome and RNA sequencing is feasible on tumor biopsies from patients refractory to atezolizumab/bevacizumab, with a small subset of patients exhibiting at least one actionable genomic alteration and receiving an adapted targeted therapy. This proof-of-concept study suggests that this clinical strategy could benefit a small subset of patients. Finally, validation of this approach will be required in a larger cohort of patients. The “French Medicine Genomic program 2025” has been designed to give patients with cancers that are refractory to systemic treatments access to off-label therapies adapted to their specific genomic profile. Herein, we reported the results of this program in patients with advanced hepatocellular carcinoma (HCC) and hepato-cholangiocarcinoma (H-CCK). In one center, all patients with HCC or H-CCK who progressed under atezolizumab/bevacizumab with available tumor frozen samples benefited from whole-genome/-exome and RNA sequencing. Targeted therapies were matched to genomic alterations following the recommendations of a molecular tumor board and radiological response and overall survival were assessed. Among 135 patients with HCC and H-CCK treated by atezolizumab/bevacizumab, 20 patients benefited from genomic analysis after progression (16 HCC; 4 H-CCK). Nineteen patients had analyzable data, 70% were male, median age was 57 years, 65% had metastatic disease and 45% had vascular invasion. Among these 19 patients, 14 patients (76%) harbored at least one actionable genomic alteration and 9/14 received an adapted targeted therapy (45%). One patient with H-CCK showing CDK4 amplification was treated with palbociclib and achieved a partial radiological response for 16 months. Another patient with H-CCK, high HER2 overexpression and a high homologous recombination score was treated with trastuzumab/olaparib and had stable disease. One patient with an HCC and bi-allelic inactivation of TSC2 achieved a complete radiological response under everolimus. The remaining six treated patients (all HCC) had progressive disease, including three patients treated with trametinib, two with everolimus and one with olaparib. Molecular-based guided therapy is feasible in patients with HCC/H-CCK progressing under atezolizumab/bevacizumab and may be useful in a small subset of patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Ava的应助被zhl采纳,获得10
刚刚
1秒前
H11103y完成签到,获得积分20
3秒前
3秒前
3秒前
3秒前
DW的应助被简单生活采纳,获得10
3秒前
hhh完成签到,获得积分10
3秒前
maomao完成签到,获得积分10
4秒前
4秒前
宁静致远发布了新的文献求助10
4秒前
lucky发布了新的文献求助10
4秒前
5秒前
5秒前
哭泣微笑的应助被嘻嘻哈哈采纳,获得210
5秒前
5秒前
PSL完成签到,获得积分10
5秒前
张伟发布了新的文献求助10
6秒前
6秒前
自信诗桃发布了新的文献求助10
6秒前
思源的应助被李楠楠采纳,获得10
7秒前
AshleyD完成签到,获得积分10
7秒前
7秒前
7秒前
vc关闭了vc的文献求助
7秒前
包容河马完成签到,获得积分10
8秒前
cdercder的应助被xu采纳,获得10
8秒前
9秒前
9秒前
9秒前
10秒前
10秒前
shark完成签到,获得积分10
10秒前
10秒前
鲁班7号发布了新的文献求助10
10秒前
Jerry完成签到,获得积分20
10秒前
10秒前
英姑的应助被宁静致远采纳,获得10
10秒前
Lily完成签到,获得积分10
10秒前
www发布了新的文献求助10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183204
求助须知:如何正确求助?哪些是违规求助? 9572482
关于积分的说明 21825940
捐赠科研通 7780074
什么是DOI,文献DOI怎么找? 3433945
关于科研通互助平台的介绍 2558060
邀请新用户注册赠送积分活动 2480166